Blab Business
Nano Dimension Announces $890 Million Term Sheet to Merge with Infinite Epigenetics, Pivoting to AI-Powered Diagnostics
On June 15, 2026, Nano Dimension Ltd. (NASDAQ: NNDM) opened a live investor call at 8:30 a.m. Eastern Time to unveil a non‑binding term sheet for a proposed merger with Infinite Epigenetics, Inc. The session, moderated by investor‑relations director Purva Sanariya, featured Nano’s President, CEO and director Dave Stehlin and Infinite’s co‑founder and CEO Dr. Matthew Dawson.
The call’s objective was to explain the strategic logic behind a business combination that would birth a publicly traded company focused on AI‑powered preventive health and diagnostics. A press release issued 16 hours earlier announced that the transaction would be structured as a merger, consolidation, or other combination, with Nano acquiring all outstanding equity of Infinite. The term sheet values Infinite at roughly $890 million, grants it majority board control, and offers legacy Nano shareholders contingent value rights.
Nano is best known for its 3D‑printing technology and associated software, but the pivot to diagnostics marks a dramatic shift from its core digital‑manufacturing business. Infinite has built a proprietary platform that uses artificial intelligence to read and interpret epigenetic signals at scale. Together, the entities aim to target a U.S. clinical diagnostics market estimated at more than $90 billion.
During the call, Sanariya highlighted a supplemental investor presentation now live on Nano’s website, which provides additional detail about the transaction. The presentation, along with the press release, outlines expected benefits such as accelerated product development, expanded clinical and commercial plans, and new reimbursement opportunities.
Both CEOs stressed that forward‑looking statements would be made during the call and cautioned that such statements are not guarantees; actual results may differ materially from any projections or expectations.
The deal remains in its early stages. The term sheet is non‑binding, and no definitive agreement has been signed. The parties have not yet disclosed a closing date or the precise governance structure of the combined entity.
From a market perspective, the transaction exemplifies a technology company moving from a manufacturing focus to a data‑driven health sector. Analysts note that the AI‑diagnostics space is expanding rapidly, driven by advances in machine learning and the growing availability of epigenetic data. The $890 million valuation reflects Infinite’s proprietary technology and its potential to capture a share of the large U.S. diagnostics market.
Investors who followed the call acknowledged that the announcement could influence Nano’s share price, although the company has not issued a guidance range. Nano’s board will review the term sheet and decide whether to proceed with a definitive agreement.
In summary, Nano Dimension has entered into a non‑binding term sheet to acquire Infinite Epigenetics, creating a new publicly traded company focused on AI‑powered preventive health and diagnostics. The transaction would shift Nano’s business model from 3D printing to data‑driven diagnostics, with Infinite receiving majority board control and Nano shareholders receiving contingent value rights. Valued at $890 million, the deal targets a U.S. diagnostics market of more than $90 billion. The parties have not yet set a closing date, and the transaction remains subject to regulatory approvals and shareholder consent.
The next steps include finalizing a definitive agreement, obtaining necessary approvals, and integrating operations. Investors will monitor updates on the transaction’s progress, potential regulatory filings, and any impact on Nano’s financial reporting and share price.
The call’s objective was to explain the strategic logic behind a business combination that would birth a publicly traded company focused on AI‑powered preventive health and diagnostics. A press release issued 16 hours earlier announced that the transaction would be structured as a merger, consolidation, or other combination, with Nano acquiring all outstanding equity of Infinite. The term sheet values Infinite at roughly $890 million, grants it majority board control, and offers legacy Nano shareholders contingent value rights.
Nano is best known for its 3D‑printing technology and associated software, but the pivot to diagnostics marks a dramatic shift from its core digital‑manufacturing business. Infinite has built a proprietary platform that uses artificial intelligence to read and interpret epigenetic signals at scale. Together, the entities aim to target a U.S. clinical diagnostics market estimated at more than $90 billion.
During the call, Sanariya highlighted a supplemental investor presentation now live on Nano’s website, which provides additional detail about the transaction. The presentation, along with the press release, outlines expected benefits such as accelerated product development, expanded clinical and commercial plans, and new reimbursement opportunities.
Both CEOs stressed that forward‑looking statements would be made during the call and cautioned that such statements are not guarantees; actual results may differ materially from any projections or expectations.
The deal remains in its early stages. The term sheet is non‑binding, and no definitive agreement has been signed. The parties have not yet disclosed a closing date or the precise governance structure of the combined entity.
From a market perspective, the transaction exemplifies a technology company moving from a manufacturing focus to a data‑driven health sector. Analysts note that the AI‑diagnostics space is expanding rapidly, driven by advances in machine learning and the growing availability of epigenetic data. The $890 million valuation reflects Infinite’s proprietary technology and its potential to capture a share of the large U.S. diagnostics market.
Investors who followed the call acknowledged that the announcement could influence Nano’s share price, although the company has not issued a guidance range. Nano’s board will review the term sheet and decide whether to proceed with a definitive agreement.
In summary, Nano Dimension has entered into a non‑binding term sheet to acquire Infinite Epigenetics, creating a new publicly traded company focused on AI‑powered preventive health and diagnostics. The transaction would shift Nano’s business model from 3D printing to data‑driven diagnostics, with Infinite receiving majority board control and Nano shareholders receiving contingent value rights. Valued at $890 million, the deal targets a U.S. diagnostics market of more than $90 billion. The parties have not yet set a closing date, and the transaction remains subject to regulatory approvals and shareholder consent.
The next steps include finalizing a definitive agreement, obtaining necessary approvals, and integrating operations. Investors will monitor updates on the transaction’s progress, potential regulatory filings, and any impact on Nano’s financial reporting and share price.
